larotrectinib

This page shows the latest larotrectinib news and features for those working in and with pharma, biotech and healthcare.

FDA gives Loxo breakthrough tag for second cancer drug

Its pipeline is headed by larotrectinib which has a BTD for patients with locally advanced or metastatic solid tumours harbouring an NTRK gene fusion mutation and has already been submitted for ... Last year, Bayer paid an impressive $400m upfront with

Latest news

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment. Loxo Oncology and Bayer should hear from the FDA about their tumour biomarker-targeted cancer drug larotrectinib by 26 November, after ... TRK inhibitor Larotrectinib is being reviewed by
Pharma sales help Bayer escape the worst from a bumpy 2017

But those failures were tempered by positive results late in the year for larotrectinib, one of two cancer assets licensed from Loxo Oncology in a $1.5bn deal. ... Larotrectinib is expected to be filed for US approval within the coming weeks, and the
Roche buys cancer company Ignyta for $1.7bn

That high level of response was behind Bayer’s decision to stump up $1.55bn to license Loxo’s larotrectinib, which is also in phase II basket trials involving patients with
Bayer gets clinical data to support $1.5bn Loxo deal

Bayer gets clinical data to support $1.5bn Loxo deal. Larotrectinib’s response rate likely to be practice changing. ... Larotrectinib’s near universal response rate and compelling durability of response in paediatric patients with TRK fusion cancers
Joerg Moeller to head Bayer R&D after operational shake-up

Among the highlights on the agenda are a look at its emerging cancer pipeline, including Loxo-sourced TRK inhibitors larotrectinib and LOXO-195 as well as projects in oncogenic signalling,

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Scientific Director / Editorial Team Leader: Great salary and benefits

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Consumer Health Account Director: Circa £60, 000 Gym and More

Director, Market Access / HEOR - North-West: Negotiable

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Production Manager – Healthcare Communications: DOE

Senior Medical Writer (Remote Working): Competitive Salary Offered

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Senior Account Executive, London, Medical Communications: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Medical Writers Required – Cheshire: DOE

New Business Director - PR: Competitive Salary and benefits

Senior Medical Writer: Great salary and benefits

Senior Medical Writer: Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Associate Medical Director: Highly Competitive

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Director: £48, 000 - £60, 000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Project / Account Manager (Medical Education): Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Systematic Review Analyst - Oxford: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...